Growth Metrics

Incyte (INCY) Income towards Parent Company (2010 - 2026)

Incyte posted quarterly Income towards Parent Company of $303.3 million for Q1 2026, up 91.73% year-on-year from $158.2 million in Q1 2025, and up 1.35% on a QoQ basis from $299.3 million in Q4 2025.

Incyte (INCY) has 17 years of Income towards Parent Company data on file, last reported at $303.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Income towards Parent Company rose 91.73% year-over-year to $303.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 6631.44% YoY), and the FY2025 full-year result was $1.3 billion, up 3844.96% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at $303.3 million, up from $299.3 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $424.2 million in Q3 2025 and bottomed at -$444.6 million in Q2 2024.
  • The 5-year median for Income towards Parent Company is $169.5 million (2024), against an average of $150.6 million.
  • Peak annual rise in Income towards Parent Company reached 681.22% in 2024, while the deepest fall reached 318.43% in 2024.
  • A 5-year view of Income towards Parent Company shows it stood at $28.5 million in 2022, then surged by 606.51% to $201.1 million in 2023, then grew by 0.07% to $201.2 million in 2024, then soared by 48.74% to $299.3 million in 2025, then increased by 1.35% to $303.3 million in 2026.
  • The last three Income towards Parent Company figures came in at $303.3 million (Q1 2026), $299.3 million (Q4 2025), and $424.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 303.33 Mn
Dec 31, 2025 299.28 Mn
Sep 30, 2025 424.17 Mn
Jun 30, 2025 405.00 Mn
Mar 31, 2025 158.20 Mn
Dec 31, 2024 201.21 Mn
Sep 30, 2024 106.46 Mn
Jun 30, 2024 -444.60 Mn
Mar 31, 2024 169.55 Mn
Dec 31, 2023 201.08 Mn
Sep 30, 2023 171.27 Mn
Jun 30, 2023 203.55 Mn
Mar 31, 2023 21.70 Mn
Dec 31, 2022 28.46 Mn
Sep 30, 2022 112.78 Mn
Jun 30, 2022 161.43 Mn
Mar 31, 2022 37.99 Mn
Dec 31, 2021 563.85 Mn
Sep 30, 2021 181.77 Mn
Jun 30, 2021 149.46 Mn
Mar 31, 2021 53.52 Mn
Dec 31, 2020 149.85 Mn
Sep 30, 2020 -15.21 Mn
Jun 30, 2020 290.30 Mn
Mar 31, 2020 -720.64 Mn
Dec 31, 2019 110.63 Mn
Sep 30, 2019 128.27 Mn
Jun 30, 2019 105.32 Mn
Mar 31, 2019 102.31 Mn
Dec 31, 2018 68.60 Mn
Sep 30, 2018 29.18 Mn
Jun 30, 2018 52.41 Mn
Mar 31, 2018 -41.14 Mn
Dec 31, 2017 -149.63 Mn
Sep 30, 2017 36.05 Mn
Jun 30, 2017 -12.48 Mn
Mar 31, 2017 -187.08 Mn
Dec 31, 2016 8.87 Mn
Sep 30, 2016 36.88 Mn
Jun 30, 2016 34.43 Mn
Mar 31, 2016 24.05 Mn
Dec 31, 2015 55.18 Mn
Sep 30, 2015 -39.58 Mn
Jun 30, 2015 9.29 Mn
Mar 31, 2015 -18.36 Mn
Dec 31, 2014 -36.94 Mn
Sep 30, 2014 59.29 Mn
Jun 30, 2014 -36.87 Mn
Mar 31, 2014 -33.96 Mn
Dec 31, 2013 -42.87 Mn
Sep 30, 2013 -22.04 Mn
Jun 30, 2013 -2.57 Mn
Mar 31, 2013 -15.67 Mn
Dec 31, 2012 18.78 Mn
Sep 30, 2012 -21.71 Mn
Jun 30, 2012 4.04 Mn
Mar 31, 2012 -45.43 Mn
Dec 31, 2011 -55.08 Mn
Sep 30, 2011 -53.08 Mn
Jun 30, 2011 -51.87 Mn
Mar 31, 2011 -26.51 Mn
Dec 31, 2010 32.54 Mn
Sep 30, 2010 -31.70 Mn
Jun 30, 2010 3.04 Mn
Mar 31, 2010 -35.73 Mn